3-Bromopyruvate induces expression of antioxidant genes

References

• Azevedo-Silva J, Queirós O, Baltazar F, et al. The anticancer agent 3-bromopyruvate: a simple but powerful molecule taken from the lab to the bedside. J Bioenerg Biomembr. 2016;48:349–362.
   PubMed Web of Science ®Google Scholar
• Pedersen PL. 3-bromopyruvate (3BP) a fast acting, promising, powerful, specific, and effective “small molecule” anti-cancer agent taken from labside to bedside: introduction to a special issue. J Bioenerg Biomembr. 2012;44:1–6.
   PubMed Web of Science ®Google Scholar
• Tan W, Zhong Z, Wang S, et al. The typical metabolic modifiers conferring improvement in cancer resistance. Curr Med Chem. 2017;24:3698–3710.
   PubMed Web of Science ®Google Scholar
• Potter M, Newport E, Morten KJ. The Warburg effect: 80 years on. Biochm Soc Trans. 2016;44:1499–1505.
   PubMed Web of Science ®Google Scholar
• San-Millán I, Brooks GA. Reexamining cancer metabolism: lactate production for carcinogenesis could be the purpose and explanation of the Warburg effect. Carcinogenesis. 2017;38:119–133.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Enríquez S, Gallardo-Pérez JC, Hernández-Reséndiz I, et al. Canonical and new generation anticancer drugs also target energy metabolism. Arch Toxicol. 2014;88:1327–1350.
   PubMed Web of Science ®Google Scholar
• Sheng H, Tang W. Glycolysis inhibitors for anticancer therapy: a review of recent patents. Recent Pat Anticancer Drug Discov. 2016;11:297–308.
   PubMed Web of Science ®Google Scholar
• Talekar M, Boreddy SR, Singh A, et al. Tumor aerobic glycolysis: new insights into therapeutic strategies with targeted delivery. Expert Opin Biol Ther. 2014;14:1145–1159.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wei J, Xu J, et al. Suppression of tumor energy supply by liposomal nanoparticle-mediated inhibition of aerobic glycolysis. Acs Appl Mater Interfaces. 2018;10:2347–2353.
   PubMed Web of Science ®Google Scholar
• Ko YH, Pedersen PL, Geschwind JF. Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. Cancer Lett. 2001;173:83–91.
   PubMed Web of Science ®Google Scholar
• Pedersen PL. Warburg, me and hexokinase 2: multiple discoveries of key molecular events underlying one of cancers’ most common phenotypes, the “Warburg Effect”, i.e., elevated glycolysis in the presence of oxygen. J Bioenerg Biomembr. 2007;39:211–222.
   PubMed Web of Science ®Google Scholar
• Ganapathy-Kanniappan S, Geschwind JF, Kunjithapatham R, et al. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is pyruvylated during 3-bromopyruvate mediated cancer cell death. Anticancer Res. 2009;29:4909–4918.
   PubMed Web of Science ®Google Scholar
• Pereira Da Silva AP, El-Bacha T, Kyaw N, et al. Inhibition of energy-producing pathways of HepG2 cells by 3-bromopyruvate. Biochem J. 2009;417:717–726.
   PubMed Web of Science ®Google Scholar
• Yadav S, Pandey SK, Kumar A, et al. Antitumor and chemosensitizing action of 3-bromopyruvate: implication of deregulated metabolism. Chem Biol Interact. 2017;270:73–89.
   PubMed Web of Science ®Google Scholar
• Kaplan RS, Pratt RD, Pedersen PL. Purification and characterization of the reconstitutively active phosphate transporter from rat liver mitochondria. J Biol Chem. 1986;261:12767–12773.
   PubMed Web of Science ®Google Scholar
• Macchioni L, Davidescu M, Roberti R, et al. The energy blockers 3-bromopyruvate and lonidamine: effects on bioenergetics of brain mitochondria. J Bioenerg Biomembr. 2014;46:389–394.
   PubMed Web of Science ®Google Scholar
• Davidescu M, Sciaccaluga M, Macchioni L, et al. Bromopyruvate mediates autophagy and cardiolipin degradation to monolyso-cardiolipin in GL15 glioblastoma cells. J Bioenerg Biomembr. 2012;44:51–60.
   PubMed Web of Science ®Google Scholar
• Davidescu M, Macchioni L, Scaramozzino G, et al. The energy blockers bromopyruvate and lonidamine lead GL15 glioblastoma cells to death by different p53-dependent routes. Sci Rep. 2015;5:14343.
   PubMed Web of Science ®Google Scholar
• El Sayed SM, Mohamed WG, Seddik MA, et al. Safety and outcome of treatment of metastatic melanoma using 3-bromopyruvate: a concise literature review and case study. Chin J Cancer. 2014;33:356–364.
   PubMedGoogle Scholar
• Cardaci S, Desideri E, Ciriolo MR. Targeting aerobic glycolysis: 3-bromopyruvate as a promising anticancer drug. J Bioenerg Biomembr. 2012;44:17–29.
   PubMed Web of Science ®Google Scholar
• Xintaropoulou C, Ward C, Wise A, et al. A comparative analysis of inhibitors of the glycolysis pathway in breast and ovarian cancer cell line models. Oncotarget. 2015;6:25677–25695.
   PubMedGoogle Scholar
• Sadowska-Bartosz I, Bartosz G. Effect of 3-bromopyruvic acid on human erythrocyte antioxidant defense system. Cell Biol Int. 2013;37:1285–1290.
   PubMed Web of Science ®Google Scholar
• Pan Q, Sun Y, Jin Q, et al. Hepatotoxicity and nephrotoxicity of 3- bromopyruvate in mice. Acta Cir Bras. 2016;31:724–729.
   PubMed Web of Science ®Google Scholar
• Sadowska-Bartosz I, Grębowski J, Kępka E, et al. ABCB1-overexpressing MDCK-II cells are hypersensitive to 3-bromopyruvic acid. Life Sci. 2016;162:138–144.
   PubMed Web of Science ®Google Scholar
• Liu Z, Sun Y, Hong H, et al. 3-bromopyruvate enhanced daunorubicin-induced cytotoxicity involved in monocarboxylate transporter 1 in breast cancer cells. Am J Cancer Res. 2015;5:2673–2685.
   PubMed Web of Science ®Google Scholar
• Kwiatkowska E, Wojtala M, Gajewska A, et al. Effect of 3-bromopyruvate acid on the redox equilibrium in non-invasive MCF-7 and invasive MDA-MB-231 breast cancer cells. J Bioenerg Biomembr. 2016;48:23–32.
   PubMed Web of Science ®Google Scholar
• Calviño E, Estañ MC, Sánchez-Martín C, et al. Regulation of death induction and chemosensitizing action of 3-bromopyruvate in myeloid leukemia cells: energy depletion, oxidative stress, and protein kinase activity modulation. J Pharmacol Exp Ther. 2014;348:324–335.
   PubMed Web of Science ®Google Scholar
• Sadowska-Bartosz I, Szewczyk R, Jaremko L, et al. Anticancer agent 3-bromopyruvic acid forms a conjugate with glutathione. Pharmacol Rep. 2016;68:502–505.
   PubMed Web of Science ®Google Scholar
• Kim JS, Ahn KJ, Kim J-A, et al. Role of reactive oxygen species-mediated mitochondrial dysregulation in 3-bromopyruvate induced cell death in hepatoma cells: ROS-mediated cell death by 3-BrPA. J Bioenerg Biomembr. 2008;40:607–618.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Zhang Y, Zhang P, et al. Hexokinase II inhibitor, 3-BrPA induced autophagy by stimulating ROS formation in human breast cancer cells. Genes Cancer. 2014;5:100–112.
   PubMedGoogle Scholar
• D'Autréaux B, Toledano MB. ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis. Nat Rev Mol Cell Biol. 2007;8:813–824.
   PubMed Web of Science ®Google Scholar
• Forman HJ, Davies KJ, Ursini F. How do nutritional antioxidants really work: nucleophilic tone and para-hormesis versus free radical scavenging in vivo. Free Radic Biol Med. 2014;66:24–35.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Yamamoto M. Stress-sensing mechanisms and the physiological roles of the Keap1-Nrf2 system during cellular stress. J Biol Chem. 2017;292:16817–16824.
   PubMed Web of Science ®Google Scholar
• El Sayed SM. Enhancing anticancer effects, decreasing risks and solving practical problems facing 3-bromopyruvate in clinical oncology: 10 years of research experience. IJN. 2018;13:4699–4709.
   Google Scholar
• Xian Shu-Lin, Cao Wei, Zhang Xiao-Dong, et al. 3-bromopyruvate inhibits human gastric cancer tumor growth in nude mice via the inhibition of glycolysis. Oncol Lett. 2015;9:739–744.
   PubMed Web of Science ®Google Scholar
• Wang Ting-An, Zhang Xiao-Dong, Guo Xing-Yu, et al. 3-bromopyruvate and sodium citrate target glycolysis, suppress survivin, and induce mitochondrial-mediated apoptosis in gastric cancer cells and inhibit gastric orthotopic transplantation tumor growth. Oncol Rep. 2016;35:1287–1296.
   PubMed Web of Science ®Google Scholar
• Ko YH, Smith BL, Wang Y, et al. Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun. 2004;324:269–275.
   PubMed Web of Science ®Google Scholar
• Ko YH, Verhoeven HA, Lee MJ, et al. A translational study “case report” on the small molecule “energy blocker” 3-bromopyruvate (3BP) as a potent anticancer agent: from bench side to bedside. J Bioenerg Biomembr. 2012;44:163–170.
   PubMed Web of Science ®Google Scholar
• Attia YM, El-Abhar HS, Al Marzabani MM, et al. Targeting glycolysis by 3-bromopyruvate improves tamoxifen cytotoxicity of breast cancer cell lines. BMC Cancer. 2015;15
   PubMed Web of Science ®Google Scholar
• Hellemans J, Vandesompele J. Selection of reliable reference genes for RT-qPCR analysis. Methods Mol Biol. 2014;1160:19–26.
   PubMedGoogle Scholar
• Fan L, Peng G, Hussain A, et al. The steroidogenic enzyme AKR1C3 regulates stability of the ubiquitin ligase Siah2 in prostate cancer cells. J Biol Chem. 2015;290:20865–20879.
   PubMed Web of Science ®Google Scholar
• Harris IS, Treloar AE, Inoue S, et al. Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression. Cancer Cell. 2015;27:211–222.
   PubMed Web of Science ®Google Scholar
• Xiong L, Xie J, Song C, et al. The activation of Nrf2 and its downstream regulated genes mediates the antioxidative activities of Xueshuan Xinmaining tablet in human umbilical vein endothelial cells. Evid Based Complement Alternat Med. 2015;2015:1.
   Google Scholar
• Lefever S, Vandesompele J, Speleman F, et al. RTPrimerDB: the portal for real-time PCR primers and probes. Nucleic Acids Res. 2009;37:D942–D945.
   PubMed Web of Science ®Google Scholar
• Pan YM, Xing R, Cui JT, et al. Clinicopathological significance of altered metallothionein 2A expression in gastric cancer according to Lauren’s classification. Chin Med J (Engl). 2013;126:2681–2686.
   PubMed Web of Science ®Google Scholar
• Javvadi P, Hertan L, Kosoff R, et al. Thioredoxin reductase-1 mediates curcumin-induced radiosensitization of squamous carcinoma cells. Cancer Res. 2010;70:1941–1950.
   PubMed Web of Science ®Google Scholar
• Sánchez-Rodríguez R, Torres-Mena JE, Quintanar-Jurado V, et al. Ptgr1 expression is regulated by NRF2 in rat hepatocarcinogenesis and promotes cell proliferation and resistance to oxidative stress. Free Radic Biol Med. 2017;102:87–99.
   PubMed Web of Science ®Google Scholar
• Stocker R. Antioxidant activities of bile pigments. Antioxid Redox Signal. 2004;6:841–849.
   PubMed Web of Science ®Google Scholar
• Chang Q, Petrash JM. Disruption of aldo-keto reductase genes leads to elevated markers of oxidative stress and inositol auxotrophy in Saccharomyces cerevisiae. Biochim Biophys Acta. 2008;1783:237–245.
   PubMed Web of Science ®Google Scholar
• Li D, Ellis EM. Aldo-keto reductase 7A5 (AKR7A5) attenuates oxidative stress and reactive aldehyde toxicity in V79-4 cells. Toxicol in Vitro. 2014;28:707–714.
   PubMed Web of Science ®Google Scholar
• Liu Y, Hyde AS, Simpson MA, et al. Emerging regulatory paradigms in glutathione metabolism. Adv Cancer Res. 2014;122:69–101.
   PubMed Web of Science ®Google Scholar
• Morgenstern R, Zhang J, Johansson K. Microsomal glutathione transferase 1: mechanism and functional roles. Drug Metab Rev. 2011;43:300–306.
   PubMed Web of Science ®Google Scholar
• Babula P, Masarik M, Adam V, et al. Mammalian metallothioneins: properties and functions. Metallomics. 2012;4:739–750.
   PubMed Web of Science ®Google Scholar
• Rundlöf AK, Arnér ES. Regulation of the mammalian selenoprotein thioredoxin reductase 1 in relation to cellular phenotype, growth, and signaling events. Antioxid Redox Signal. 2004;6:41–52.
   PubMed Web of Science ®Google Scholar
• Reichelt ME, Shanu A, Willems L, et al. Endogenous adenosine selectively modulates oxidant stress via the A1 receptor in ischemic hearts. Antioxid Redox Signal. 2009;11:2641–2650.
   PubMed Web of Science ®Google Scholar